RecruitingNCT01852448

Genetics of Insulin and Incretins in Cystic Fibrosis

Evaluation of the Enteroinsular Axis in Cystic Fibrosis


Sponsor

Children's Hospital of Philadelphia

Enrollment

550 participants

Start Date

May 1, 2013

Study Type

OBSERVATIONAL

Conditions

Summary

Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes. The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load). This study will examine the prevalence of Genome wide association study (GWAS)-implicated T2DM alleles (including TCF7L2) across the spectrum of glucose abnormalities in CF and will use this information to compare incretin and insulin secretion in non-diabetic children and adults with high risk and low risk alleles.


Eligibility

Min Age: 2 Years

Inclusion Criteria3

  • Subjects age >2y
  • Diagnosis of Cystic Fibrosis
  • For subjects< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICBlood or Saliva Sample Collection

A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.


Locations(2)

The Children's Hopsital of Philadelphia

Philadelphia, Pennsylvania, United States

The University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01852448


Related Trials